"A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of BR6002 and Coadministration of BR6002A and BR6002B Under Fed Conditions in Healthy Adult Volunteers"

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

September 12, 2023

Study Completion Date

September 12, 2023

Conditions
Gastric or Duodenal Ulcer
Interventions
DRUG

BR6002A

One tablet administered alone

DRUG

BR6002B

One tablet administered alone

DRUG

BR6002

One capsule administered alone

Trial Locations (1)

08779

Clinical Research Center, H PLUS Yangji Hospital, Seoul

All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY